{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T18:40:07Z","timestamp":1751740807348,"version":"3.41.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,5]]},"DOI":"10.7759\/cureus.87343","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T18:10:47Z","timestamp":1751739047000},"source":"Crossref","is-referenced-by-count":0,"title":["Symptom Reduction and Deprescribing in a Patient With Treatment-Resistant Depression Using Sublingual Ketamine Troches: A Case Report"],"prefix":"10.7759","author":[{"given":"Elizabeth","family":"Francis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion","volume":"178","author":"McIntyre RS","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, et al.. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion. Am J Psychiatry. 2021, 178:383-99. 10.1176\/appi.ajp.2020.20081251","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011612.pub3","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"9","author":"Dean RL","year":"2021","unstructured":"Dean RL, Hurducas C, Hawton K, et al.. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021, 9:CD011612. 10.1002\/14651858.CD011612.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre RS","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, et al.. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023, 22:394-412. 10.1002\/wps.21120","journal-title":"World Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.992624","article-title":"Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: a retrospective study of off-label, at-home use","volume":"13","author":"Hassan K","year":"2022","unstructured":"Hassan K, Struthers WM, Sankarabhotla A, Davis P. Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: a retrospective study of off-label, at-home use. Front Psychiatry. 2022, 13:992624. 10.3389\/fpsyt.2022.992624","journal-title":"Front Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5798285","article-title":"A review of nonanesthetic uses of ketamine","volume":"2020","author":"Pribish A","year":"2020","unstructured":"Pribish A, Wood N, Kalava A. A review of nonanesthetic uses of ketamine. Anesthesiol Res Pract. 2020, 2020:5798285. 10.1155\/2020\/5798285","journal-title":"Anesthesiol Res Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.07.004","article-title":"At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial","volume":"314","author":"Hull TD","year":"2022","unstructured":"Hull TD, Malgaroli M, Gazzaley A, et al.. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial. J Affect Disord. 2022, 314:59-67. 10.1016\/j.jad.2022.07.004","journal-title":"J Affect Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.1061","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review","volume":"8","author":"Walsh Z","year":"2021","unstructured":"Walsh Z, Mollaahmetoglu OM, Rootman J, et al.. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. 2021, 8:e19. 10.1192\/bjo.2021.1061","journal-title":"BJPsych Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001, 16:606-13. 10.1046\/j.1525-1497.2001.016009606","journal-title":"J Gen Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1037\/t02591-000","article-title":"Generalized Anxiety Disorder 7","author":"Spitzer RL","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, et al.. Generalized Anxiety Disorder 7. American Psychiatric Association, Washington, DC; 2006. 10.1037\/t02591-000"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-26","article-title":"The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in major depressive disorder","volume":"9","author":"Fantino B","year":"2009","unstructured":"Fantino B, Moore N. The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in major depressive disorder. BMC Psychiatry. 2009, 9:26. 10.1186\/1471-244X-9-26","journal-title":"BMC Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos P","year":"2018","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018, 23:801-11. 10.1038\/mp.2017.255","journal-title":"Mol Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15404","article-title":"Long-term safety and efficacy of sublingual ketamine troches\/lozenges in chronic non-malignant pain management","volume":"52","author":"Maudlin B","year":"2022","unstructured":"Maudlin B, Gibson SB, Aggarwal A. Long-term safety and efficacy of sublingual ketamine troches\/lozenges in chronic non-malignant pain management. Intern Med J. 2022, 52:1538-43. 10.1111\/imj.15404","journal-title":"Intern Med J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2023.2169349","article-title":"Oral ketamine for depression: an updated systematic review","volume":"24","author":"Meshkat S","year":"2023","unstructured":"Meshkat S, Haikazian S, Di Vincenzo JD, et al.. Oral ketamine for depression: an updated systematic review. World J Biol Psychiatry. 2023, 24:545-57. 10.1080\/15622975.2023.2169349","journal-title":"World J Biol Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2018.196","article-title":"Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"214","author":"Domany Y","year":"2019","unstructured":"Domany Y, Bleich-Cohen M, Tarrasch R, et al.. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019, 214:20-6. 10.1192\/bjp.2018.196","journal-title":"Br J Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383995-symptom-reduction-and-deprescribing-in-a-patient-with-treatment-resistant-depression-using-sublingual-ketamine-troches-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T18:10:47Z","timestamp":1751739047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383995-symptom-reduction-and-deprescribing-in-a-patient-with-treatment-resistant-depression-using-sublingual-ketamine-troches-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.87343","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,5]]}}}